Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immunic, Inc.
  6. News
  7. Summary
    IMUX   US4525EP1011

IMMUNIC, INC.

(IMUX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunic : Prices $45 Million Common Stock Offering

07/15/2021 | 10:53am EDT


ę MT Newswires 2021
All news about IMMUNIC, INC.
09/08IMMUNIC, INC. : to Participate in Investor and Scientific Conferences in Septemb..
PR
09/08PRESS RELEASE : Immunic, Inc. to Participate in Investor and Scientific Conferen..
DJ
09/07IMMUNIC : HC Wainwright Adjusts Immunic's Price Target to $25 from $40, Keeps Bu..
MT
08/09IMMUNIC : Wedbush Adjusts Immunic's Price Target to $61 From $68, Citing Stock D..
MT
08/06IMMUNIC, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/06IMMUNIC : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/06IMMUNIC : Q2 Earnings Snapshot
AQ
08/06IMMUNIC, INC. : Reports Second Quarter 2021 Financial Results and Highlights Rec..
PR
08/06IMMUNIC : Earnings Flash (IMUX) IMMUNIC Reports Q2 Loss $-0.82
MT
08/06Immunic, Inc. Reports Unaudited Consolidated Earnings Results for the Second ..
CI
More news
Analyst Recommendations on IMMUNIC, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -92,6 M - -
Net cash 2021 101 M - -
P/E ratio 2021 -2,38x
Yield 2021 -
Capitalization 247 M 247 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 45
Free-Float 75,4%
Chart IMMUNIC, INC.
Duration : Period :
Immunic, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNIC, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,42 $
Average target price 54,50 $
Spread / Average Target 479%
EPS Revisions
Managers and Directors
Daniel Vitt President, Chief Executive Officer & Director
Glenn Whaley VP-Finance, Chief Financial & Accounting Officer
Duane D. Nash Executive Chairman
Hella Kohlhof Chief Scientific Officer
Andreas Muehler Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMUNIC, INC.-38.39%247
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850